Friday’s Midday Stock Update: Anthera Pharmaceuticals (ANTH), Vivus (VVUS), Akorn (AKRX), ImmunoCellular Therapeutics (IMUC), Titan Pharmaceuticals (TTNP)

So far Friday, December 7, NASDAQ is down -5.06% and the S&P is down -3.68%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Anthera Pharmaceuticals (ANTHResearch Report), Vivus (VVUSResearch Report), Akorn (AKRXResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report) and Titan Pharmaceuticals (TTNPResearch Report).

Anthera Pharmaceuticals is up 55.26% in midday trading to $0.06. Shares opened today at $0.04. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Vivus is up 19.92% in midday trading to $3.07. Shares opened today at $2.56. The company has a 52-week low of $2.52 and a 52-week high of $0.00. In the last 30 days, insiders purchased $40.7K worth of VVUS shares. Over the last 3 months, the insider sentiment on Vivus has been positive based on 40 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Akorn is down -18.9% in midday trading to $4.52. Shares opened today at $5.57. The company has a 52-week low of $3.54 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $13.80, marking a 147.76% potential upside from current levels. In a report issued on November 27, Piper Jaffray analyst David Amsellem reiterated a Buy rating on AKRX, with a price target of $9, which represents a potential upside of 62% from where the stock is currently trading. Separately, on November 7, RBC’s Randall Stanicky maintained a Hold rating on the stock and has a price target of $9.

See today’s analyst top recommended stocks >>

ImmunoCellular Therapeutics is down -10.71% in midday trading to $0.03. Shares opened today at $0.03. The company has a 52-week low of $0.02 and a 52-week high of $0.00.

Titan Pharmaceuticals is up 10.46% in midday trading to $0.29. Shares opened today at $0.26. The company has a 52-week low of $0.17 and a 52-week high of $0.00. Over the last 3 months, the insider sentiment on Titan Pharmaceuticals has been positive based on 7 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Leave a Reply

Your email address will not be published. Required fields are marked *